Breast cancer rates on the increase
http://www.emfacts.com/weblog/index.php?p=641
--------
Breast Cancer....re inflammation and immune dysfunction...2004
From: JCMPelican @aol.com
Date: Mon, 12 Feb 2007 07:16:55 EST
DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS IMMUNE SUPPRESSION AND INFLAMMATION IN THE PROGRESSION OF BREAST CANCER BUNT, STEPHANIE K INSTITUTION: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY 2004 BREAST CANCER RESEARCH PROGRAM PREDOCTORAL TRAINEESHIP AWARD $90,000.00
Public Abstract
Breast cancer is characterized by a deterioration of the body's natural immune response and generalized immune suppression. Systemic suppression, associated with a poor prognosis, prevents tumor-bearing individuals from mounting an effective immune response against the growing tumor. This lack of immunity is the result of T and B cell dysfunction and the suppression of other key cells involved in the immune response. As a result of this immune dysfunction, many current cancer vaccine therapies are ineffective in breast cancer patients because these therapies rely on the patients' natural immune system to function effectively. The presence of systemic immune suppression in breast cancer patients is partly due to the presence of myeloid suppressor cells (MSCs), which are immature precursor cells that amass in the spleen and blood in proportion to tumor burden. MSCs are believed to suppress the immune system by secreting reactive species that induce immune dysfunction, preventing the patient from mounting an immune response against the growing tumor. Currently, the pathway and mechanisms behind the accumulation and suppressive functions of MSCs are poorly understood.
Inflammation, the body's localized tissue response to injury or trauma, is thought to promote the development and progression of breast cancer, potentially through the promotion of immune suppression. Interleukin 1beta (IL-1beta), a pro-inflammatory cytokine involved in the inflammatory response, has been implicated in the development of malignancies and is known to be expressed in breast cancer. Our preliminary studies associate immune suppression in breast cancer with the production of IL-1beta, indicating that inflammation is involved in the suppression of immunity. This study will examine the mechanisms by which inflammation and IL-1beta induce immune suppression in a breast cancer model.
We hypothesize that IL-1beta enhances immune suppression and inhibits natural immune surveillance against mammary tumors. Preliminary experiments using 4T1 mouse mammary carcinoma cells that have been engineered to secrete IL-1beta confirm that IL-1beta enhances cancer-associated immune suppression by promoting the accumulation of MSCs in tumor bearing mice. The proposed study will characterize the population of IL-1beta-induced MSCs in tumor-bearing mice and determine the mechanism by which IL-1beta promotes immune suppression through MSCs. To accomplish this goal, we will functionally characterize this subpopulation of MSCs and identify the target immune cells that are suppressed by the MSCs. We will determine how these immune target cells are inactivated and the mechanism by which IL-1beta induces MSC accumulation. To further examine the relevance of inflammation in the development and progression of mammary cancers, anti-inflammatory drugs (NSAIDs) will be administered to mice prior to tumor onset and the effect of reducing inflammation on immune suppression and mammary cancer will be determined.
Understanding the link between inflammation and immune suppression in breast cancer is essential for the development of cancer therapies. The mechanisms by which immune suppression is induced and maintained may be targeted in the development of therapies designed to circumvent this suppression and boost the body's natural tumor surveillance. The ability to prevent systemic immune suppression will enhance the efficacy of current cancer therapies in breast cancer patients. This study will be especially valuable in evaluating the role of inflammation in breast cancer by evaluating the effect of anti-inflammatory drugs in breast cancer and their potential use in the treatment of breast cancer.
http://cdmrp.army.mil/scripts/get_item.asp?item=abstract&log_no=BC043242&type=public
--------
Breast cancer....heating pads on "list of suspects?"
http://www.buergerwelle.de/pdf/breast_cancer_heating_pads_on_list_of_suspects.htm
--------
Autism rates increase as sources of electro magnetic radiation increase
http://omega.twoday.net/stories/3302024/
http://omega.twoday.net/search?q=breast+cancer
http://omega.twoday.net/search?q=Australian+Broadcasting+Corporation
--------
Breast Cancer....re inflammation and immune dysfunction...2004
From: JCMPelican @aol.com
Date: Mon, 12 Feb 2007 07:16:55 EST
DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS IMMUNE SUPPRESSION AND INFLAMMATION IN THE PROGRESSION OF BREAST CANCER BUNT, STEPHANIE K INSTITUTION: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY 2004 BREAST CANCER RESEARCH PROGRAM PREDOCTORAL TRAINEESHIP AWARD $90,000.00
Public Abstract
Breast cancer is characterized by a deterioration of the body's natural immune response and generalized immune suppression. Systemic suppression, associated with a poor prognosis, prevents tumor-bearing individuals from mounting an effective immune response against the growing tumor. This lack of immunity is the result of T and B cell dysfunction and the suppression of other key cells involved in the immune response. As a result of this immune dysfunction, many current cancer vaccine therapies are ineffective in breast cancer patients because these therapies rely on the patients' natural immune system to function effectively. The presence of systemic immune suppression in breast cancer patients is partly due to the presence of myeloid suppressor cells (MSCs), which are immature precursor cells that amass in the spleen and blood in proportion to tumor burden. MSCs are believed to suppress the immune system by secreting reactive species that induce immune dysfunction, preventing the patient from mounting an immune response against the growing tumor. Currently, the pathway and mechanisms behind the accumulation and suppressive functions of MSCs are poorly understood.
Inflammation, the body's localized tissue response to injury or trauma, is thought to promote the development and progression of breast cancer, potentially through the promotion of immune suppression. Interleukin 1beta (IL-1beta), a pro-inflammatory cytokine involved in the inflammatory response, has been implicated in the development of malignancies and is known to be expressed in breast cancer. Our preliminary studies associate immune suppression in breast cancer with the production of IL-1beta, indicating that inflammation is involved in the suppression of immunity. This study will examine the mechanisms by which inflammation and IL-1beta induce immune suppression in a breast cancer model.
We hypothesize that IL-1beta enhances immune suppression and inhibits natural immune surveillance against mammary tumors. Preliminary experiments using 4T1 mouse mammary carcinoma cells that have been engineered to secrete IL-1beta confirm that IL-1beta enhances cancer-associated immune suppression by promoting the accumulation of MSCs in tumor bearing mice. The proposed study will characterize the population of IL-1beta-induced MSCs in tumor-bearing mice and determine the mechanism by which IL-1beta promotes immune suppression through MSCs. To accomplish this goal, we will functionally characterize this subpopulation of MSCs and identify the target immune cells that are suppressed by the MSCs. We will determine how these immune target cells are inactivated and the mechanism by which IL-1beta induces MSC accumulation. To further examine the relevance of inflammation in the development and progression of mammary cancers, anti-inflammatory drugs (NSAIDs) will be administered to mice prior to tumor onset and the effect of reducing inflammation on immune suppression and mammary cancer will be determined.
Understanding the link between inflammation and immune suppression in breast cancer is essential for the development of cancer therapies. The mechanisms by which immune suppression is induced and maintained may be targeted in the development of therapies designed to circumvent this suppression and boost the body's natural tumor surveillance. The ability to prevent systemic immune suppression will enhance the efficacy of current cancer therapies in breast cancer patients. This study will be especially valuable in evaluating the role of inflammation in breast cancer by evaluating the effect of anti-inflammatory drugs in breast cancer and their potential use in the treatment of breast cancer.
http://cdmrp.army.mil/scripts/get_item.asp?item=abstract&log_no=BC043242&type=public
--------
Breast cancer....heating pads on "list of suspects?"
http://www.buergerwelle.de/pdf/breast_cancer_heating_pads_on_list_of_suspects.htm
--------
Autism rates increase as sources of electro magnetic radiation increase
http://omega.twoday.net/stories/3302024/
http://omega.twoday.net/search?q=breast+cancer
http://omega.twoday.net/search?q=Australian+Broadcasting+Corporation
Starmail - 4. Feb, 18:32
